Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
REDWOOD CITY, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on January 15, 2016, the compensation committee of the company’s board of directors granted 12 new employees options to purchase an aggregate of 39,000 shares of the company’s common stock with a per share exercise price of $19.44, the closing trading price on the grant date, and 19,500 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, VeltassaTM (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
